European filing for Janssen's canagliflozin/metformin diabetes combo
This article was originally published in Scrip
Executive Summary
Johnson & Johnson's Janssen-Cilag unit has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat adult patients with type 2 diabetes.